Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin.

abstract：BACKGROUND:Understanding the effect size, variability, and underlying physiology of the dawn phenomenon is important for next-generation closed-loop control algorithms for type 1 diabetes (T1D). SUBJECTS AND METHODS:We used an iterative protocol design to study 16 subjects with T1D on individualized insulin pump thera...

journal_title：Diabetes technology & therapeutics

authors： Mallad A,Hinshaw L,Dalla Man C,Cobelli C,Basu R,Lingineni R,Carter RE,Kudva YC,Basu A

更新日期：2015-08-01 00:00:00

abstract：BACKGROUND:Stress-induced hyperglycemia is prevalent in critical care, even in patients with no history of diabetes. Increased counter-regulatory hormone response increases gluconeogenesis and effective insulin resistance, which can be exacerbated by drug therapy. Control of blood glucose levels to the 4.0-6.1 mmol/L r...

journal_title：Diabetes technology & therapeutics

authors： Lonergan T,Compte AL,Willacy M,Chase JG,Shaw GM,Hann CE,Lotz T,Lin J,Wong XW

更新日期：2006-08-01 00:00:00

abstract：OBJECTIVE:Hemoglobin A1c (A1C) has recently been recommended for diagnosing diabetes mellitus and diabetes risk (prediabetes). Its performance compared with fasting plasma glucose (FPG) and 2-h post-glucose load (2HPG) is not well delineated. We compared the performance of A1C with that of FPG and 2HPG in preoperative ...

journal_title：Diabetes technology & therapeutics

authors： Gianchandani RY,Saberi S,Zrull CA,Patil PV,Jha L,Kling-Colson SC,Gandia KG,DuBois EC,Plunkett CD,Bodnar TW,Pop-Busui R

更新日期：2011-12-01 00:00:00

abstract：AIMS:This study evaluated treatment satisfaction, comfort, and function using the wireless OmniPod™ Insulin Management System (Insulet Corp., Bedford, MA) compared with conventional (infusion set) insulin pumps in young adults with type 1 diabetes. RESEARCH DESIGN AND METHODS:Twenty-nine patients (age, 24.0 ± 5.1 year...

journal_title：Diabetes technology & therapeutics

authors： Lebenthal Y,Lazar L,Benzaquen H,Shalitin S,Phillip M

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:The hyperinsulinemic euglycemic clamp is the gold standard for assessment of insulin resistance and requires frequent, accurate measurements of blood glucose concentrations, typically utilizing the YSI 2300 STAT Plus™ glucose analyzer (YSI, Inc., Yellow Springs, OH). Despite its accuracy, the YSI has several...

journal_title：Diabetes technology & therapeutics

authors： Lindquist KA,Chow K,West A,Pyle L,Isbell TS,Cree-Green M,Nadeau KJ

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:Children with positive islet autoantibodies monitored prospectively avoid metabolic decompensation at type 1 diabetes (T1D) diagnosis. However, the effects of early diagnosis and treatment on preservation of insulin secretion and long-term metabolic control are unknown. We compared characteristics of childre...

journal_title：Diabetes technology & therapeutics

authors： Chan CL,Taki I,Dong F,Hoffman M,Norris JM,Klingensmith G,Rewers MJ,Steck AK

更新日期：2015-09-01 00:00:00

abstract：:Patients with diabetes play with a double-edged sword when it comes to deciding glucose and A1c target levels. On the one side, tight control has been shown to be crucial in avoiding long-term complications; on the other, tighter control leads to an increased risk of iatrogenic hypoglycemia, which is compounded when h...

journal_title：Diabetes technology & therapeutics

authors： Palerm CC,Willis JP,Desemone J,Bequette BW

更新日期：2005-02-01 00:00:00

abstract：:Type 2 diabetes is thought to develop as a result of progressive beta-cell dysfunction in the setting of insulin resistance, leading to increased risks of microvascular and macrovascular complications. Type 2 diabetes is currently treated with diet and exercise, followed by oral drug therapy, and finally exogenous ins...

journal_title：Diabetes technology & therapeutics

authors： Kendall DM,Kim D,Maggs D

更新日期：2006-06-01 00:00:00

abstract：BACKGROUND:Various insulin delivery systems have been considered for systemic absorption other than injections. Although the ocular route has been suggested, its use is limited by the amount of insulin absorbed systemically via eyes. In order to improve the absorption rate of insulin into systemic circulations, the eff...

journal_title：Diabetes technology & therapeutics

authors： Xuan B,McClellan DA,Moore R,Chiou GC

更新日期：2005-10-01 00:00:00

abstract：:Most previous attempts at the development of a "smart tattoo" for glucose monitoring in diabetes--implantable fluorescent microspheres that can be implanted intradermally and interrogated transdermally using light--have focused on the encapsulation of a competitive binding assay for glucose within hydrogel microsphere...

journal_title：Diabetes technology & therapeutics

authors： Brown JQ,Srivastava R,Zhu H,McShane MJ

更新日期：2006-06-01 00:00:00

abstract：BACKGROUND:We assessed the impact of using an automated bolus advisor integrated into a blood glucose meter on the timing and frequency of adjusting insulin therapy parameter settings and whether the availability of this technology would increase blood glucose test strip utilization in diabetes patients treated with mu...

journal_title：Diabetes technology & therapeutics

authors： Cavan DA,Ziegler R,Cranston I,Barnard K,Ryder J,Vogel C,Parkin CG,Koehler W,Vesper I,Petersen B,Schweitzer MA,Wagner RS

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:The value of self-monitoring of blood glucose (SMBG) for persons with type 2 diabetes who do not use insulin remains controversial. This observational study compares the likelihood of medication adherence and change in glycated hemoglobin (A1C) for non-insulin-using patients using SMBG versus those not using...

journal_title：Diabetes technology & therapeutics

authors： Virdi N,Daskiran M,Nigam S,Kozma C,Raja P

更新日期：2012-09-01 00:00:00

abstract：BACKGROUND:Applying real-time learning into an artificial pancreas system could effectively track the unpredictable behavior of glucose-insulin dynamics and adjust insulin treatment accordingly. We describe a novel learning algorithm and its performance when integrated into the MD-Logic Artificial Pancreas (MDLAP) syst...

journal_title：Diabetes technology & therapeutics

authors： Miller S,Nimri R,Atlas E,Grunberg EA,Phillip M

更新日期：2011-10-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Hyperglycemia occurs commonly in patients admitted to medical intensive care units (MICUs). Whether real-time (RT) continuous glucose monitoring (CGM) improves glycemic control and variability and reduces hypoglycemia in severely ill MICU patients with an Acute Physiology and Chronic Health Eva...

journal_title：Diabetes technology & therapeutics

authors： De Block CE,Gios J,Verheyen N,Manuel-y-Keenoy B,Rogiers P,Jorens PG,Scuffi C,Van Gaal LF

更新日期：2015-12-01 00:00:00

abstract：:It is becoming increasingly acknowledged that people with Type 2 Diabetes represent what can be termed "an enriched population": a group that has the greatest risk of morbidity and mortality from cardiovascular diseases such as myocardial infarcts and strokes. Due to the tremendous toll, both human and financial, that...

journal_title：Diabetes technology & therapeutics

authors： Marcus AO

更新日期：2000-07-01 00:00:00

abstract：:Glucose oxidase has had a central role in previous glucose sensing methods and is key to the development of certain new glucose sensors. The immobilized enzyme is specific for glucose and sufficiently long-lived for many sensor applications, but new glucose sensing applications may place increased demands on the enzym...

journal_title：Diabetes technology & therapeutics

authors： Gough DA,Bremer T

更新日期：2000-10-01 00:00:00

abstract：BACKGROUND:This article reports a prolonged trial with insulin pumps implanted in patients with type 1 diabetes showing poor glucose control and a high rate of complications. METHODS:We reviewed data from 181 patients undergoing implanted insulin pump therapy. Analysis included hemoglobin A1c (HbA1c) values, body weig...

journal_title：Diabetes technology & therapeutics

authors： Schaepelynck P,Renard E,Jeandidier N,Hanaire H,Fermon C,Rudoni S,Catargi B,Riveline JP,Guerci B,Millot L,Martin JF,Sola A,EVADIAC Group.

更新日期：2011-06-01 00:00:00

abstract：:Many people with insulin-treated diabetes continue to experience inadequate glycemic control and a high incidence of hypoglycemic events, despite improvements in therapeutic strategies. While glycated hemoglobin (HbA1c) is currently recognized as the gold-standard for assessing glycemic control, the measure reflects m...

journal_title：Diabetes technology & therapeutics

authors： Battelino T,Edelman SV,Nishimura R,Bergenstal RM

更新日期：2021-01-01 00:00:00

abstract：: Background: The financial strain of type 1 diabetes on the United States health care system, patients, and employers underscores the importance of developing novel treatments for the disease. This study estimated the lifetime economic burden attributable to type 1 diabetes...

journal_title：Diabetes technology & therapeutics

authors： Sussman M,Benner J,Haller MJ,Rewers M,Griffiths R

更新日期：2020-02-01 00:00:00

abstract：: Background: Glycemic variability (GV) is an important component of glycemic control for patients with type 1 diabetes (T1D). The inadequacy of existing measurements lies in the fact that they view the variability from different aspects, so that no consensus has been reache...

journal_title：Diabetes technology & therapeutics

authors： Zheng F,Jalbert M,Forbes F,Bonnet S,Wojtusciszyn A,Lablanche S,Benhamou PY

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:The present study evaluated the efficacy of biphasic human insulin 30 (BHI 30) in type 2 diabetes patients who had failed in therapy with two or more oral antidiabetes drugs (OADs). METHODS:This open-label, nonrandomized, 4-month, multicenter, clinical observational study was conducted in Shanghai, China. A...

journal_title：Diabetes technology & therapeutics

authors： Gu Y,Hou X,Zhang L,Pan J,Cai Q,Bao Y,Jia W

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:Proper healing of ulcers and wounds on the feet of diabetes patients is important in order to prevent amputation. If the wound area reduction during the first 4 weeks of the treatment is not 40% or more, reevaluation of the treatment is necessary. The wound area evaluation is not complicated when the patient...

journal_title：Diabetes technology & therapeutics

authors： Foltynski P,Ladyzynski P,Migalska-Musial K,Sabalinska S,Ciechanowska A,Wojcicki J

更新日期：2011-08-01 00:00:00

abstract：BACKGROUND:Computer simulation environments have been used in the development of many artificial pancreas systems. A glucose sensor model is an essential part of these environments, and different models have been proposed. However, not one of these models accounts for drop-outs of sensor readings, a well-known phenomen...

journal_title：Diabetes technology & therapeutics

authors： Emami A,Rabasa-Lhoret R,Haidar A

更新日期：2015-06-01 00:00:00

abstract：BACKGROUND:Drugs with unspecific stimulating effects on beta-cell secretion increase the homeostasis model assessment (HOMA)-B score, indicating improved beta-cell "function." We investigated whether the beta-cell protection provided by adding pioglitazone (PIO) to glimepiride (GLIM) in comparison to up-titrating the G...

journal_title：Diabetes technology & therapeutics

authors： Pfützner A,Derwahl M,Jacob S,Hohberg C,Blümner E,Lehmann U,Fuchs W,Forst T

更新日期：2010-08-01 00:00:00

abstract：: Aims: We evaluated the real-life efficacy and safety of empagliflozin in combination with optimized insulin therapy in patients with type 1 diabetes (T1D). Methods: This was a prospective study, including 27 patients with T1D t...

journal_title：Diabetes technology & therapeutics

authors： Bayona Cebada A,Nattero-Chávez L,Alonso Díaz S,Escobar-Morreale HF,Luque-Ramírez M

更新日期：2020-03-01 00:00:00

abstract：:Current clinical guidelines for diabetes care encourage self-monitoring of blood glucose (SMBG) to improve glycemic control. Specific protocols remain variable, however, particularly among non-insulin-using patients. This is due in part to efficacy studies that neglect to consider (1) the performance of monitoring equ...

journal_title：Diabetes technology & therapeutics

authors： Hirsch IB,Bode BW,Childs BP,Close KL,Fisher WA,Gavin JR,Ginsberg BH,Raine CH,Verderese CA

更新日期：2008-12-01 00:00:00

abstract：:Type 2 diabetes is characterized by insulin resistance and progressive β-cell deterioration. As β-cell function declines, most patients with type 2 diabetes treated with oral agents, in monotherapy or combination, will require insulin therapy. Addition of basal insulin (glargine, detemir, or NPH/neutral protamine lisp...

journal_title：Diabetes technology & therapeutics

authors： Ampudia-Blasco FJ,Rossetti P,Ascaso JF

更新日期：2011-06-01 00:00:00

abstract：AIMS:Recent advances in analytical technology allow the detection of several hundred volatile organic compounds (VOCs) in human exhaled air, many of which reflect unidentified endogenous pathways. This study was performed to determine whether a breath gas analysis using proton transfer reaction-mass spectrometry (PTR-M...

journal_title：Diabetes technology & therapeutics

authors： Greiter MB,Keck L,Siegmund T,Hoeschen C,Oeh U,Paretzke HG

更新日期：2010-06-01 00:00:00

abstract：BACKGROUND:Performance of continuous glucose monitors (CGMs) may be lower when glucose levels are changing rapidly, such as occurs during physical activity. Our aim was to evaluate accuracy of a current-generation CGM during moderate-intensity exercise in type 1 diabetes (T1D) pregnancy. SUBJECTS AND METHODS:As part o...

journal_title：Diabetes technology & therapeutics

authors： Kumareswaran K,Elleri D,Allen JM,Caldwell K,Nodale M,Wilinska ME,Amiel SA,Hovorka R,Murphy HR

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:There is no consensus as to the best method to assess glycemic variability from continuous glucose monitoring (CGM) data. Rate of change has been suggested as a preferred method of assessing glycemic variability, but this assertion has not been validated. METHODS:Forty-eight hours of CGM data were analyzed ...

journal_title：Diabetes technology & therapeutics

authors： Whitelaw BC,Choudhary P,Hopkins D

更新日期：2011-06-01 00:00:00